Gastric Balloon — Cost, Top Hospitals & Success Rates | MyMedicPlus

The intragastric balloon is a non-surgical weight loss intervention in which a soft silicone balloon is placed inside the stomach via endoscopy and inflated with saline solution (typically 400–700 mL) to partially fill the gastric cavity. By occupying space within the stomach, the balloon induces early satiety, reduces total meal volume, and slows gastric emptying — thereby reducing caloric intake and promoting weight loss over the treatment period.

The procedure is performed endoscopically under conscious sedation or light general anaesthesia as a day procedure without incisions. The deflated balloon is introduced through the mouth via an endoscope, positioned in the stomach, and inflated with saline mixed with methylene blue dye (which colours the urine blue if the balloon deflates — providing a safety signal). The balloon remains in place for 6 months (standard) before endoscopic removal, as longer durations increase complication risk. A second balloon may be placed for a further 6 months in some programmes.

The gastric balloon is a short-term tool to initiate weight loss momentum, and must be used alongside a structured dietary, exercise, and behavioural change programme to optimise results and sustain weight loss after balloon removal. It is intended as a bridge to lifestyle change rather than a permanent weight management solution.

Gastric balloon treatment is indicated for overweight and obese patients (BMI 27–40 kg/m²) who wish to lose weight without surgery, who have not responded adequately to diet and exercise alone, and who are motivated to engage with a comprehensive lifestyle modification programme. It is particularly appropriate for patients who are too low a BMI for surgical bariatric procedures but sufficiently overweight to benefit from structured intervention.

Patients requiring significant pre-operative weight loss before major surgery (orthopaedic joint replacement, cardiac surgery) may use gastric balloon as a bridging weight reduction strategy. Non-alcoholic fatty liver disease (NAFLD/NASH) with elevated liver enzymes and liver steatosis may improve with the weight loss achieved through balloon treatment. The balloon also has an application in motivating patients who are considering but uncertain about bariatric surgery, giving them experience of reduced food intake and weight loss while they decide on long-term options.

Ideal candidates are adults aged 18–65 with BMI between 27 and 40 kg/m² who have made serious attempts at dietary and lifestyle modification without achieving or sustaining adequate weight loss, are committed to a supervised dietary and exercise programme during and after balloon treatment, and have no absolute contraindications to endoscopy or balloon placement.

Contraindications include previous gastric surgery (Billroth, sleeve, bypass — altered anatomy prevents safe placement or increases complication risk), large hiatus hernia (increases reflux risk and balloon instability), inflammatory conditions of the gastrointestinal tract (active gastric ulcer, oesophagitis, Crohn's disease of the stomach), bleeding disorders or anticoagulation preventing safe endoscopy, known allergy to silicone components, pregnancy, uncontrolled psychiatric illness (particularly eating disorders — binge eating, purging behaviours), and heavy alcohol use.

Orbera intragastric balloon (Apollo Endosurgery) is the most extensively studied and widely used device, placed endoscopically and filled with 400–700 mL saline. It remains in place for 6 months and is removed endoscopically. Orbera360 is a sequential balloon programme providing two 6-month balloons in succession for up to 12 months of treatment.

Obalon swallowable balloon (Orbera SmartBall predecessor) — delivered in a capsule swallowed without endoscopy and inflated with gas via a connecting tube — is an alternative that avoids sedation for placement. Spatz3 adjustable balloon (Spatz Medical) can be partially deflated or inflated in-situ endoscopically to accommodate patient tolerance — useful when early intolerance requires volume reduction, and balloon volume can subsequently be increased for sustained restriction. Endoscopic sleeve gastroplasty (ESG) using the Overstitch suturing system is a more durable non-balloon endoscopic approach that creates a sleeve-like reduction of the gastric cavity — longer lasting than balloon, with 15–20% total body weight loss at 24 months.

Selecting the most appropriate Gastric Balloon approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

Clinical trials report total body weight loss of 10–15% (approximately 12–15 kg) during the 6-month balloon period for the Orbera device. The REDUCE pivotal trial showed Orbera achieved 7.6% total body weight loss versus 3.1% for lifestyle modification alone. Metabolic benefits including improved HbA1c, blood pressure, lipid profile, and liver steatosis accompany weight loss. Quality of life and physical functioning improvements are consistently reported.

The critical variable is weight maintenance after balloon removal — patients who engage fully with the lifestyle programme during and after balloon treatment maintain significantly more weight loss at 12 months than those who do not. Studies report maintenance of 70–85% of balloon-period weight loss at 12 months in patients who complete the programme. The balloon serves best as a catalyst for sustainable behaviour change rather than as a solution in itself.

Early adverse effects occur in 90% of patients within the first 3–5 days after balloon placement: nausea, vomiting, abdominal cramps, and reflux from gastric irritation and distension. Antiemetic and proton pump inhibitor medications are prescribed prophylactically, and most symptoms resolve within 3–7 days as the stomach adapts. Approximately 5–7% of patients require early removal due to intolerable symptoms.

Serious complications include spontaneous balloon deflation (1–3%), which requires prompt endoscopic removal — the methylene blue dye in the saline turns urine green/blue, alerting the patient. Deflated balloons can migrate to the small intestine causing bowel obstruction (less than 0.3%). Gastric ulceration at the balloon contact point occurs in 1–4% and is managed with PPI therapy; perforation is extremely rare (under 0.1%). Balloon hyperinflation from bacterial growth in the saline can occur after prolonged placement, emphasising the importance of removal at 6 months.

Monthly follow-up visits with the bariatric dietitian and nutritionist are essential during the 6-month balloon period to support dietary changes, physical activity adoption, and behavioural modification. A proton pump inhibitor (omeprazole 20–40 mg daily) is prescribed for the full duration to reduce gastric acid and ulceration risk. Monthly weight and body composition measurements track progress.

At 6 months, balloon removal is performed endoscopically under the same conscious sedation used for placement — a 15–20 minute procedure. The balloon is deflated by puncturing with a needle and the saline aspirated before withdrawal through the mouth. A post-removal dietary programme maintaining caloric restriction and continued lifestyle modification is essential to prevent rebound weight gain, which is the most common limitation of balloon therapy.

Gastric balloon treatment in the United States costs USD 6,000–12,000 for the complete 6-month programme including placement, removal, and dietary programme. It is rarely covered by insurance as it is considered an elective weight loss procedure. In the UK, private gastric balloon costs approximately GBP 3,500–5,500.

Medical tourism significantly reduces costs: gastric balloon placement and removal in India costs USD 1,500–3,000, in Thailand USD 2,500–4,500, in Turkey USD 2,000–4,000, and in Mexico USD 2,500–4,500 — savings of 60–75%. Look for centres that include dietitian support and follow-up in the package, as the structured programme is as important as the procedure itself.

Several key factors determine the final cost of Gastric Balloon: clinical complexity of the individual case, the specific technique or protocol selected, specialist time required, imaging and laboratory testing, implant or device costs where applicable, and the duration of post-treatment monitoring. Geographic location exerts a strong influence — urban tertiary-care centres in high-income countries charge premium rates, while equivalent accredited care in India, Thailand, Turkey, and Mexico provides comparable clinical outcomes at 50–75% lower cost. Patients seeking international treatment should factor in travel, accommodation, and the cost of follow-up care on return home. Private health insurance coverage varies considerably; patients should obtain pre-authorisation in writing and confirm what components of the treatment pathway are included. Many patients access government healthcare subsidies or medical financing plans to spread the cost of elective and semi-elective procedures.

Endoscopic sleeve gastroplasty (ESG) creates a sleeve-like gastric reduction endoscopically without incisions and achieves 15–20% total body weight loss at 24 months — more than gastric balloon — with a lower re-gain rate. It is a more durable non-surgical option for appropriate candidates.

Pharmacological weight management with GLP-1 receptor agonists (semaglutide 2.4 mg weekly — Wegovy) achieves average 15% total body weight loss at 68 weeks in the STEP-1 trial — comparable to or exceeding balloon outcomes with no procedural risk, though it requires indefinite medication. Dual GIP/GLP-1 agonist tirzepatide (Mounjaro) achieves up to 22% body weight loss. For patients with BMI over 35 and significant comorbidities, surgical bariatric procedures (sleeve gastrectomy, RYGB) provide more powerful and durable weight loss than the balloon.